Recently, the team of Prof. Zhang Yi from the First Affiliated Hospital of ZZU has made new progress in the research of colorectal cancer tumor immune microenvironment and new targets for immunotherapy. The related research fruits were published in both Hematology & Oncology and Journal for ImmunoTherapy of Cancer with Prof. Zhang Yi as the corresponding author and ZZU First Affiliated Hospital as independent author unit. The research was headed by Prof. Zhang Yi, funded by the National Natural Science Foundation of China’s joint key and major research project.

Both studies employ a variety of research methods to study the internal mechanisms of chemokines and their receptors influencing the development of chemotherapy resistance and immunotherapy efficacy in patients with colorectal cancer from different levels. It analyzes the impact of tumor immune microenvironment on tumor treatment, seeks to break immunosuppression and reverse the cold tumor microenvironment, explore effective treatment targets for colorectal cancer, and provide new ideas for clinical treatment of colorectal cancer patients.